Literature DB >> 26947495

Safety of classical swine fever virus vaccine strain LOM in pregnant sows and their offspring.

Seong-In Lim1, Jae-Young Song1, Jaejo Kim1, Bang-Hun Hyun1, Ha-Young Kim1, In-Soo Cho1, Byounghan Kim1, Gye-Hyeong Woo2, Jung-Bok Lee3, Dong-Jun An4.   

Abstract

The present study aimed to evaluate the safety of the classical swine fever virus (CSFV) vaccine strain LOM in pregnant sows. Pregnant sows with free CSFV antibody were inoculated with a commercial LOM vaccine during early pregnancy (day 38; n=3) or mid-pregnancy (days 49-59; n=11). In pregnant sows vaccinated during the early stages of gestation, abortion (day 109) was observed in one case, with two stillbirths and seven mummified fetuses. The viability of live-born piglets was 34.9% in sows vaccinated during mid-pregnancy compared with 81.8% in the control group. Post-mortem examination of the organs of the sows and piglets did not reveal any pathological lesions caused by CSFV; however, CSFV RNA was detected in the organs of several vaccinated sows and their litters. The LOM strain was transmitted from sows with free CSFV antibody to their fetus, but did not appear to induce immune tolerance in the offspring from vaccinated pregnant sows. Side effects were not observed in pregnant sows with antibody to the LOM strain: transmission from sow to their litters and stillbirth or mummified fetuses. The LOM strain may induce sterile immunity and provide rapid, long-lasting, and complete protection against CSFV; however, it should be contraindicated in pregnant sows due to potential adverse effects in pregnant sows with free CSFV antibody.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Classical swine fever virus; LOM strain; Pregnant sows; Safety

Mesh:

Substances:

Year:  2016        PMID: 26947495     DOI: 10.1016/j.vaccine.2016.02.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Adverse Effects of Classical Swine Fever Virus LOM Vaccine and Jeju LOM Strains in Pregnant Sows and Specific Pathogen-Free Pigs.

Authors:  SeEun Choe; Jae-Hoon Kim; Ki-Sun Kim; Sok Song; Ra Mi Cha; Wan-Choul Kang; Hyeun-Ju Kim; Gyu-Nam Park; Jihye Shin; Hyoung-Nam Jo; In-Soo Cho; Bang-Hun Hyun; Bong-Kyun Park; Dong-Jun An
Journal:  Pathogens       Date:  2019-12-23

2.  A multiplex RT-PCR assay for rapid and simultaneous detection of four RNA viruses in swine.

Authors:  Yan Zhao; Feifei Liu; Qingmei Li; Mengfan Wu; Lei Lei; Zishu Pan
Journal:  J Virol Methods       Date:  2019-04-02       Impact factor: 2.014

3.  Evaluation of classical swine fever E2 (CSF-E2) subunit vaccine efficacy in the prevention of virus transmission and impact of maternal derived antibody interference in field farm applications.

Authors:  Jing-Yuan Chen; Chi-Ming Wu; Zeng-Weng Chen; Chih-Ming Liao; Ming-Chung Deng; Min-Yuan Chia; Chienjin Huang; Maw-Sheng Chien
Journal:  Porcine Health Manag       Date:  2021-01-11

4.  Comparative Analysis of the Productivity and Immunogenicity of an Attenuated Classical Swine Fever Vaccine (LOM) and an Attenuated Live Marker Classical Swine Fever Vaccine (Flc-LOM-BErns) from Laboratory to Pig Farm.

Authors:  SeEun Choe; Ki-Sun Kim; Jihye Shin; Sok Song; Gyu-Nam Park; Ra Mi Cha; Sung-Hyun Choi; Byung-Il Jung; Kyung-Won Lee; Bang-Hun Hyun; Bong-Kyun Park; Dong-Jun An
Journal:  Vaccines (Basel)       Date:  2021-04-13

5.  Classical Swine Fever Outbreak after Modified Live LOM Strain Vaccination in Naive Pigs, South Korea.

Authors:  Sang H Je; Taeyong Kwon; Sung J Yoo; Dong-Uk Lee; SeungYoon Lee; Juergen A Richt; Young S Lyoo
Journal:  Emerg Infect Dis       Date:  2018-04       Impact factor: 6.883

6.  Impact of a Live Attenuated Classical Swine Fever Virus Introduced to Jeju Island, a CSF-Free Area.

Authors:  SeEun Choe; Jae-Hoon Kim; Ki-Sun Kim; Sok Song; Wan-Choul Kang; Hyeon-Ju Kim; Gyu-Nam Park; Ra Mi Cha; In-Soo Cho; Bang-Hun Hyun; Bong-Kyun Park; Dong-Jun An
Journal:  Pathogens       Date:  2019-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.